FDA advisers have recommended that six controversial peptides be added to the US 503A Bulks List — potentially opening the door to broader pharmacy compounding of compounds that have become increasingly popular in the online wellness and longevity space.
The Pharmacy Compounding Advisory Committee (PCAC) voted in favour of BPC-157, KPV, TB-500, MOTS-C, epitalon and semax during a two-day meeting on 23-24 July.
Emideltide was the only peptide to be rejected.
The recommendations are not equivalent to FDA approval and the agency is not required to follow the committee's advice.
However, a positive decision would allow state-licensed 503A compounding pharmacies to use the substances in compounded medicines, subject to the requirements governing pharmaceutical compounding.
Missing evidence
This development could have significant implications for the peptide supply chain.
BPC-157, TB-500 and related compounds have built a substantial following among fitness and wellness consumers — despite limited human clinical evidence — with products frequently marketed online for applications including tissue repair, recovery, anti-ageing and weight management.
The FDA has, however, previously raised concerns about several of the compounds.
For example, its assessment of BPC-157 cites limited safety information and potential risks relating to immunogenicity, peptide-related impurities and API characterisation.
For TB-500, the agency has said it has identified no human exposure data for drug products containing the peptide and also highlighted potential risks associated with aggregation and impurities.
Similar concerns have been raised around MOTS-C and semax.
Production challenges
For manufacturers and ingredient suppliers, the regulatory shift could therefore create opportunities as well as new quality and compliance requirements.
Peptide APIs can present specific manufacturing challenges, including controlling impurities and aggregation, maintaining product consistency and managing immunogenicity risks.
The FDA's 503A framework also requires bulk substances used by compounders to meet applicable standards and be accompanied by a valid certificate of analysis, with the agency advising compounders to scrutinise their bulk-drug suppliers.
Watch and wait...
The committee's votes have been closely watched by the industry as they could signal a change in direction following the FDA's earlier concerns about these substances.
The outcome also highlights the widening gap between consumer demand for peptide therapies and the conventional drug-development pathway.
While supporters argue that regulated compounding could bring greater oversight to a largely grey-market sector, critics continue to question whether the available evidence supports wider clinical use.
For the pharma manufacturing sector, the next step will be waiting for the FDA's response. Until the agency takes its own action, the advisory committee's recommendations do not themselves make the six peptides FDA-approved medicines, or automatically permit their use in compounding.
